If you only test children with family history, you miss the majority
For a decade in Bavaria, researchers quietly pursued a question that sits at the heart of preventive medicine: can we find illness before it finds us? A study of more than 220,000 children, conducted through ordinary pediatric offices rather than specialized clinics, has demonstrated that routine screening for early-stage type 1 diabetes is not only feasible but catches the vast majority of children before crisis strikes. The findings, now published in JAMA, challenge the long-held assumption that only children with family history need watching — and open a door to a future where diagnosis arrives as preparation rather than emergency.
- Type 1 diabetes typically announces itself through crisis — excessive thirst, weight loss, and the dangerous metabolic emergency of diabetic ketoacidosis — but the immune attack on the pancreas begins silently, years earlier.
- The Fr1da study found that most children who developed clinical diabetes had no family history of the disease, meaning screening programs built around family risk alone are missing the majority of cases.
- Once autoimmunity begins, children progress through disease stages at a consistent rate of roughly 20 percent per year, underscoring that the window for intervention is real but not unlimited.
- A second round of screening three years after the first caught 29 additional children who had not yet developed autoimmune markers — suggesting that a single early test is not enough and rescreening is warranted.
- Early detection is now translating into something tangible: families gain time to prepare, access specialized care, and potentially qualify for disease-modifying therapies that may delay or prevent insulin dependence altogether.
Since 2015, researchers at Helmholtz Munich have been running an experiment inside the ordinary rhythms of childhood healthcare. Through 716 private pediatric practices across Bavaria, they enrolled more than 220,000 children in a study called Fr1da — testing small blood samples for islet autoantibodies, the molecular signals that appear years before any symptom of type 1 diabetes emerges. The results, now published in JAMA after a full decade of follow-up, are striking: early-stage disease was found in roughly 0.3 percent of children screened, and 81 percent of those who eventually developed clinical diabetes were identified in advance.
The significance of early detection lies in what it prevents. Type 1 diabetes typically surfaces only after the immune system has been attacking the pancreas for years — by which point children face not just a new diagnosis but the risk of diabetic ketoacidosis, a severe and potentially life-threatening metabolic emergency. Catching the disease at stage 1, when autoimmunity has begun but blood sugar remains normal, gives families and clinicians time to prepare rather than react.
One of the study's most consequential findings was also one of its most counterintuitive: the majority of children who progressed to clinical diabetes had no family history of the disease. This directly challenges the logic of risk-based screening, which has traditionally focused resources on children with affected relatives. Dr. Christiane Winkler, who leads the Fr1da team, concluded that population-wide screening is the only approach that captures most cases.
The study also mapped the disease's internal rhythm. Children moved through the three stages of type 1 diabetes at a consistent rate of about 20 percent per year — a finding that tells researchers the pancreatic damage begins from the moment the immune system turns against it, and that any meaningful intervention must come early. A second screening conducted roughly three years after the first identified 29 more children who had since developed autoimmune markers, making the case that a single test in early childhood is insufficient.
For families who receive a positive result, the message is not that their child is sick today — it is that they now have time. Time for education, for monitoring, for access to specialized centers, and potentially for emerging disease-modifying therapies that may slow or halt progression before insulin dependence begins. The Fr1da researchers believe their decade of evidence has proven that this kind of screening belongs in routine pediatric care everywhere, not just in Bavaria.
A decade-long investigation in Bavaria has quietly reshaped how doctors might think about childhood diabetes. Since 2015, researchers at Helmholtz Munich have been asking a straightforward question: can we catch type 1 diabetes before it becomes an emergency? The answer, now published in JAMA, is yes—and the evidence is substantial enough to change practice.
The Fr1da study enrolled more than 220,000 children through 716 pediatricians in ordinary private practices across Bavaria. This was not a specialized research setting. It was routine care. At each visit, a small blood sample was tested for islet autoantibodies—markers that appear years before a child shows any symptoms of diabetes. The researchers found early-stage disease in about 0.3 percent of the children screened. Over the course of follow-up, 212 of those 590 children progressed to clinical type 1 diabetes. That represents 81 percent of all the children who eventually developed the disease.
The timing matters. Type 1 diabetes typically announces itself long after it has begun. Children develop excessive thirst, lose weight, grow fatigued. By then, the disease has often advanced to a dangerous point. If it goes undetected, diabetic ketoacidosis—a severe metabolic emergency—can follow. The Fr1da researchers wanted to know whether catching the disease earlier, when the body's immune system is just beginning to attack the pancreas but blood sugar remains normal, could change that trajectory. The answer appears to be yes.
One finding surprised the researchers. Most children who developed clinical type 1 diabetes had no family history of the disease. This upends a common assumption in screening: that you should focus on high-risk families. If doctors only tested children with a relative who had diabetes, they would miss the majority of cases. Dr. Christiane Winkler, who leads the Fr1da team, put it plainly: screening the general population makes sense. The disease does not discriminate by family history.
The study also revealed something about how the disease unfolds. Once autoimmunity begins, the progression is remarkably consistent. Children moved from stage 1 (early autoimmunity, normal blood sugar) to stage 2 (early autoimmunity, impaired glucose metabolism) to stage 3 (clinical diabetes requiring insulin) at roughly the same rate—about 20 percent per year. This suggests the pancreatic damage is happening from the moment the immune system turns against it. For researchers designing future treatments, this is crucial information. It means interventions need to start early, not wait for symptoms.
A second screening, conducted about three years after the first, identified 29 additional children with early-stage disease. Some children develop the autoimmune markers later in childhood. This finding supports the case for rescreening: a single test at age three misses children who develop the disease a few years later.
For families who receive a positive screening result, the news is not that their child has diabetes or needs insulin immediately. It is that their child's immune system has begun attacking the pancreas, and they now have time to prepare. Families receive education and access to specialized diabetes centers. Doctors can monitor how quickly the child's metabolism is changing. The goal is to catch the transition to clinical diabetes early enough to prevent ketoacidosis and, potentially, to offer new disease-modifying therapies that might delay or prevent the disease altogether.
The researchers see this as a foundation for broader change. If the disease process is the same in children with and without family history, then screening should be offered to all children, not just those at high genetic risk. And if early detection works, then the therapies being developed to slow or stop the disease can be tested and deployed before children become insulin-dependent. The Fr1da study has shown that this kind of screening is sustainable in ordinary pediatric practice. The question now is whether health systems will adopt it.
Notable Quotes
If we only test children with a family history of type 1 diabetes, we miss the majority of children who later develop stage 3 type 1 diabetes.— Dr. Christiane Winkler, Helmholtz Munich
The disease process in the pancreas is happening from the outset of autoimmunity and potentially transforms our approach to the timing of therapies.— Prof. Anette-Gabriele Ziegler, Helmholtz Munich
The Hearth Conversation Another angle on the story
Why does it matter that most children who develop type 1 diabetes have no family history?
Because it means you can't rely on family trees to find the disease. If you only screen children whose parents or siblings have diabetes, you'll catch maybe one in five cases. The other four will slip through until they're sick enough to need emergency care.
So the screening itself is the point—not the family history.
Exactly. The screening is what works. And it's simple: a blood test at a regular pediatric visit. No special equipment, no specialized center. That's why this study matters. They proved you can do this in any doctor's office.
What changes if you catch it early?
Everything, potentially. Right now, most children don't know they have diabetes until they're in crisis—severe thirst, weight loss, sometimes a medical emergency. If you catch it when the autoimmunity starts but blood sugar is still normal, families have time to prepare. Doctors can monitor closely. And new treatments being developed might actually slow or stop the disease before insulin becomes necessary.
How fast does it progress once you find it?
About 20 percent of children move to the next stage each year. So if you find it at stage one, there's a decent window—maybe a few years—before clinical diabetes develops. That's time to intervene.
Why does the study recommend a second screening?
Because some children don't develop the autoimmune markers until later in childhood. The first screening at age three catches most cases, but a second test a few years later finds children who developed the disease a little later. It's not expensive, and it catches cases the first test missed.
What's the barrier to making this routine?
Not the science—the study proves it works and it's feasible. It's probably just inertia. Changing how doctors practice takes time. But the evidence is now strong enough that it should happen.